How to Scale Your Med-Tech Business

Scaling a MedTech business from £2m to £20m revenue requires navigating a uniquely complex ecosystem: regulatory bodies, clinical evidence requirements, long NHS procurement cycles, and quality systems. This guide walks founders through critical decisions that determine success.

R egulatory burden compounds exponentially. A software update is a feature release. A MedTech update is a regulatory submission. CE marking in Europe, UK Conformity Assessment post-Brexit, and FDA in the US each require separate dossiers, evidence packages, and months of review.

Clinical evidence is non-negotiable. Payers—NHS, NICE, private insurers—won't reimburse without proof of clinical benefit and health economic value. This demands randomised controlled trials (RCTs), real-world evidence (RWE), health economic models, and QALY calculations. A single RCT costs £4–15m and takes 3–5 years.

Sales cycles are brutal. NHS procurement involves tenders, health economics reviews, trust engagement, and budget holder sign-off. Average time from first conversation to first order: 18–24 months. Private acute chains move faster (8–12 months) but demand lower prices.

Supply chain and manufacturing constraints are real. ISO 13485 (medical device quality management) certification takes 12–18 months and demands investment in systems, training, and supplier audits. At scale, you'll hit component shortages, regulatory audits, and rising compliance costs.

---

Pathway	Timeline	Key Cost	Evidence Needed
CE Marking (UKCA)	6–18 months	£200–600k	Technical dossier, biocompatibility, performance data
FDA 510(k)	6–12 months	£300–800k	Predicate device, performance equivalence
FDA PMA	2–5 years	£3–8m	RCT, manufacturing specs, long-term safety
NICE HTA	18–24 months	£500k–2m	RCT, QALY, cost-effectiveness model

UK Conformity Assessment (UKCA): Post-Brexit, CE markings no longer automatically register in the UK. UKCA requires a UK Notified Body—same evidence as CE, but separate submission. Many founders submit both simultaneously to cover EU and UK markets.

FDA 510(k) vs. PMA: 510(k) is fast (6–12 months) if a predicate device exists. PMA is slow but mandatory for high-risk devices. Plan for PMA if your device makes clinical claims on its own or is truly novel.

---

Real-World Evidence (RWE): RCTs are gold standard but expensive. RWE—using registry data, observational studies, or patient cohorts—is increasingly accepted by NICE and private payers. At £2–5m revenue, you'll likely mix small RCTs with RWE to build your economic case faster and cheaper.

NICE Health Technology Assessment (HTA): NICE's Single Technology Assessment costs £500k–1m and takes 18–24 months. It's required for NHS reimbursement. Start health economic modelling early: model your device's cost-effectiveness against standard care and factor in implementation costs.

QALYs (Quality-Adjusted Life Years): NICE uses QALYs to measure value. A device that adds one year of perfect health = 1 QALY. If it costs £30k, NICE views it as cost-effective. Your health economics team must understand utility measurement and discount rates. Hire or contract a health economist—non-negotiable for NHS scale.

---

Integrated Care Systems (ICSs): Post-NHS reorganisation, purchasing power consolidated in 42 ICBs across England. Rather than selling to 150+ trusts, you now target regional ICBs. This speeds early-stage sales but makes adoption uneven.

Private Acute Hospitals: Spire, BMI, and other private chains move faster (8–12 months) and bypass NICE. Margins are higher but volume is lower. Use private sales to generate RWE for NHS later.

---

---

Contract Manufacturing (CDMO) vs. In-House: Early stage (£1–5m), contract manufacture with a certified CDMO. This avoids capital, speeds time-to-market, and lets you scale flexibly. Cost: 15–40% of COGS depending on complexity. As revenue scales past £8–10m, building in-house capacity often becomes cheaper and gives you control.

ISO 13485 Certification: Non-negotiable for any MedTech manufacturing. Certification takes 12–18 months and costs £50–150k. It covers design, manufacturing, testing, complaint handling, and traceability. Budget for a Quality Manager by £3m revenue.

Supply Chain: MedTech supply chains are complex. A single component supplier's failure can halt your entire business. Dual-source critical components. Maintain 3–6 months inventory for long-lead items. FDA and EU audits will interrogate your supply chain risk.

---

File utility patents (core technology), design patents (form factor), and method patents (clinical use) in your target markets: UK, EU, US, Japan. Full patent prosecution in all territories costs £50–150k per family. At £2m revenue, you'll likely file selectively: UK/EU first (cheaper), then US (mandatory for US market).

Trade Secrets: Manufacturing processes, clinical data, health economic models, and supplier relationships can be more valuable than patents. Invest in confidentiality agreements and secure data systems.

Freedom to Operate: Before launching, conduct FTO analysis to ensure you're not infringing competitor patents. At £3m+ revenue, budget annual FTO reviews.

---

Innovate UK SBRI: Non-dilutive grants up to £3m for healthcare innovation. Competitive but valuable for early clinical trials and health economic studies. Deadlines quarterly.

Wellcome Trust Seed Awards: Up to £200k for healthcare innovators. Great for prototype validation and clinical feasibility studies.

MedTech-Specialist VCs: Firms like BGF Healthcare, Triple Point, and Ascension Ventures understand MedTech timelines. Series A (£2–8m) is standard at £1–3m revenue if you've achieved regulatory approval and early NHS traction. Series B (£8–20m) typically funds commercial scale-up and evidence generation.

Strategic Partners: Larger MedTech companies or healthcare distributors often invest in or acquire early-stage innovators. Strategic capital can be faster than VC but comes with obligations around product roadmap. Evaluate carefully.

Pricing for Sustainability: NHS reimbursement is tight. Private/international markets fund your R&D. Model revenue in three channels: NHS (40–50% volume, lower margin), private UK (20–30%, 30–40% margin), and international (10–20%, variable). Ensure total blended margin sustains your burn rate.

---

CE → FDA → Asia Strategy: Most successful UK founders pursue CE first (6–18 months), then FDA 510(k) (6–12 months) or PMA (2–5 years). FDA opens US market. Asia (Japan, South Korea, Singapore) follows if you've proven product-market fit.

Market Selection: France, Germany, Spain are EU markets with strong reimbursement. Germany's faster health economics review makes it a common second market. Australia and Canada have streamlined pathways for CE-marked devices. Choose 2–3 markets first; expand methodically.

Reimbursement Divergence: A device cost-effective for NHS (£30k/QALY) may not meet German or US thresholds. Price and positioning shift by region. Budget for localized health economic models.

Distribution: Most successful US/Asia expansion uses distributors or agents, not direct sales. A distributor takes 20–40% margin but handles regulatory navigation, reimbursement, and local sales.

---

• Underestimating clinical evidence timelines. Plan for 3–5 years of evidence generation alongside sales. Use RWE to accelerate reimbursement decisions.
• Hiring sales reps from software. MedTech sales require clinical credibility and patience. Hire healthcare veterans or clinical staff who can transition to sales.
• Ignoring health economics early. NICE and payers ask for cost-effectiveness models from first conversation. Engage a health economist by £1m revenue.
• Betting everything on NHS. NHS is slow to adopt and tightly budgeted. Build private and international revenue concurrently to sustain growth.
• Skipping supply chain risk. A supplier failure in Year 3 can halt your scale-up. Dual-source critical components and maintain inventory discipline from day one.
• Misunderstanding regulatory harmonisation. CE does not equal FDA. Each pathway demands separate submissions and evidence. Budget time and money accordingly.